Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
Ellinor Elinder, Jonas Bergh, Anne Andersson, Henrik Lindman, Jamila Adra, Yvonne Brandberg, Mats Hellström, Thomas Hatschek, Hemming Johansson, Aglaia Schiza, Hanna Fredholm, Ann Charlotte Dreifaldt, Edward Azavedo, Lena M. S. Carlsson, Ioannis Zerdes, Erika Isaksson-Friman, Ana Bosch, Johan Hartman, Susanne Agartz, Gyula Pekar, Tobias Lekberg, Zakaria Einbeigi, Per Grybäck, Claudia Maes, Theodoros Foukakis, Judith Bjöhle
Publikováno v:
JAMA Oncol
Importance Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential of T-DM1 as monotherapy is so far unknown. Objective To assess pathologic c
Autor:
Peter C. Lucas, Marc J. Gollub, Tracey E. Schefter, Bryan A. Faller, Richard K. Valicenti, Mark A O'Rourke, William Parker, Greg Yothers, Philip J. Stella, Samuel A. Jacobs, Osama E. Rahma, Radhika Kainthla, Thomas J. George, Y. Nancy You, Lisa A. Kachnic, Elin R. Sigurdson, Katherine M. Moxley, Norman Wolmark, Theodore S. Hong, William A. Hall, Namrata Vijayvergia, Linda H. Colangelo, Marcia M. Russell
Publikováno v:
JAMA Oncol
Importance Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As such, novel combinations
Autor:
Werner Lichtenegger, Georg Heinrich, Inga Bekes, Julia Jückstock, Thomas W. P. Friedl, Robert E. Coleman, Matthias W. Beckmann, Volkmar Müller, Sara Y. Brucker, Ralf Lorenz, Sven Mahner, Wolfgang Janni, Hans Tesch, Andreas Schneeweiss, Tanja Fehm, Lothar Häberle, Helmut Forstbauer, Jens Uwe Blohmer, Visnja Fink, Peter A. Fasching, Jens Huober, Brigitte Rack
Publikováno v:
JAMA Oncol
Importance Bisphosphonate treatment in patients with early breast cancer has become part of care, but the optimal treatment duration is still unclear. Objective To compare 2 vs 5 years of zoledronate treatment following adjuvant chemotherapy in patie
Autor:
Sze Huey Tan, Jibin Li, Mei Lin, Rui You, Guo-Ping Shen, Yi-Shan Wu, Yi-Jun Hua, Rou Jiang, Lin-Quan Tang, Ming-Yuan Chen, Rui Sun, Yu-Long Xie, Li Ling, Yong Chen, Yu-Xiang He, You-Ping Liu, Qiu-Yan Chen, Xiong Zou, Hong-Dan Zhang, Qing Liu, Jing-Yu Cao, Meng-Xia Zhang, Chong-Yang Duan, Melvin L.K. Chua, Yi-Nuan Zhang, Zhi-Qiang Wang, Ai-Hua Zhuang, Pei Yu Huang, Qi Yang, Ling Guo, Hao-Yuan Mo, Hai-Qiang Mai
Publikováno v:
JAMA Oncology. 6:1345
Importance The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear. Objective To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC. Design, Setting, and Parti
Autor:
Martin Sökler, Ulrich Keller, Carsten Kobe, Bastian von Tresckow, Andreas Rosenwald, Stephan Mathas, Paul J Bröckelmann, Michael Fuchs, Jasmin Mettler, Julia Meissner, Peter Borchmann, Andrea Kerkhoff, Andreas Zimmermann, Stephanie Sasse, Wolfram Klapper, Helen Goergen, Rainer Ordemann, Andreas Engert, Matthias Bormann, Teresa V Halbsguth, Christian Baues, Andreas Hüttmann
Publikováno v:
JAMA Oncol
Importance In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects. Nivolumab is well tolerated and highly effective in relapsed/refractory cHL but ha
Autor:
Shunichi Sugawara, Kazuhiko Nakagawa, Hiroshi Nokihara, Isamu Okamoto, Hiroaki Okamoto, Haruyasu Murakami, Seiji Niho, Nobuyuki Yamamoto, Atsushi Horiike, Masahiko Ando, Yuka Fujita, Yukio Hosomi, Yasuto Yoneshima, Hidehito Horinouchi, Koichi Azuma, Shogo Nomura, Tomohiro Ozaki, Yuichiro Ohe, Shinji Atagi
Publikováno v:
Transl Lung Cancer Res
Importance Few clinical trials have been specifically designed for elderly patients with advanced non–small cell lung cancer (NSCLC), and the anticipated increase in the number of such patients has prompted a search for new treatment options that p
Autor:
Nikolaus Schultz, Jeffrey A. Drebin, Kian-Huat Lim, William C. Chapman, Anna M. Varghese, Ryan C. Fields, M.B. Majella Doyle, Andrea Cercek, Thomas Boerner, Leonard B. Saltz, Peter J. Allen, Neeta Vachharajani, Diane Reidy-Lagunes, Michael I. D’Angelica, Haley Hauser, Taryn M. Boucher, Mithat Gonen, Steven M. Strasberg, Richard K. G. Do, Nancy E. Kemeny, Ronald P. DeMatteo, William G. Hawkins, William R. Jarnagin, Luis A. Diaz, T. Peter Kingham, Joanne F. Chou, Benjamin R. Tan, James J. Harding, Vinod P. Balachandran, Maeve A. Lowery, Francisco Sanchez-Vega
Publikováno v:
JAMA Oncol
Importance Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. Objectiv
Autor:
James J. Harding, Ghassan K. Abou-Alfa, Vincent C. Tam, Benjamin R. Tan, Alan P. Venook, Philip E. Lammers, Jennifer Balletti, Imane El Dika, Qian Shi, James Posey, Robin Kate Kelley, Richard M. Goldberg, Tanios Bekaii-Saab, R. Goel, Monica M. Bertagnolli, Donna Niedzwiecki, Eileen M. O'Reilly, Tyler Zemla, Ryan I. Potaracke, Jennifer Marie Suga, Petr Kavan, Lawrence H. Schwartz, Jennifer J. Knox, Jeffrey A. Meyerhardt, Lakshmi Rajdev, Anthony B. El-Khoueiry, Andreas Kaubisch
Publikováno v:
Ann Transl Med
JAMA Oncol
JAMA Oncol
Importance Previous communication has reported significant improvement in overall survival (OS) when using doxorubicin plus sorafenib in the treatment of advanced hepatocellular cancer (HCC). Objective To determine if doxorubicin added to sorafenib t
Autor:
Qi-Jiong Li, Wan-Qiang Fang, Ruhai Zou, Min-Ke He, Yuan-Min Zhou, Wei Wei, XiaoPing Wu, Ming Zhao, Ming Shi, Jingxian Shen, Rong Ping Guo, Zhongguo Zhou, Ying Guo, GuoSheng Tan, Minshan Chen, Li Xu, Yong Le
Publikováno v:
JAMA Oncology. 5:953
Importance Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil,
Autor:
Eric Winquist, Bingshu E. Chen, Andrew Pearce, J. Butler, Lillian L. Siu, George Shenouda, Martin Chasen, Alexander Montenegro, S. Breen, John Waldron, Brian O'Sullivan, Abdenour Nabid, Timothy Childs, Ana P. Johnson, John H. Hay, Jolie Ringash, Geoffrey Liu, Wendy R. Parulekar, Eric X. Chen, J. Wright, Thomas J. Fitzgerald
Publikováno v:
JAMA Oncology. 3:220
Importance The Canadian Cancer Trials Group study HN.6 is the largest randomized clinical trial to date comparing the concurrent administration of anti–epidermal growth factor receptor (EGFR) monoclonal antibodies with radiotherapy (RT) to standard